Dr. Kothari Featured in New Retina Radio Podcast
Texas Retina’s Nikisha Kothari, MD, recently participated in a new podcast released by the New Retina Radio Journal Club and Vit-Buckle Society. In it, she discusses research published earlier this year in
read more
Happy Thanksgiving!
All Texas Retina Associates offices will be closed Thursday, November 28, and Friday, November 29, for the Thanksgiving holiday. During this time of reflection and gratitude, we want you to know how
read more
How Smoking Can Affect Your Eye Health
Today is the Great American Smokeout. Smoking remains the single largest cause of preventable disease and premature death in the United States. You probably know that smoking increases your risk of developing
read more
Dr. Coors Treats First Patient in DAYBREAK Clinical Trial of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer for Wet AMD
Texas Retina’s Lori E. Coors, MD, recently enrolled and treated the first patient in the Phase III DAYBREAK trial evaluating an intravitreal tarcocimab tedromer and tabirafusp tedromer compared with intravitreal aflibercept in
read more
Happy Veterans Day!
On behalf of everyone at Texas Retina, we would like to extend our deepest gratitude for the sacrifices that our service members, both past and present, have made for our country.
read more
Dr. Abbey Presented at the Outpatient Ophthalmic Surgery Society (OOSS) Symposium 2024
Texas Retina’s Ashkan Abbey, MD, recently presented “Innovation in Retina for the ASC” at the Outpatient Ophthalmic Surgery Society (OOSS) Symposium 2024. He highlighted the advantages and disadvantages of several recent surgical
read more
Texas Retina’s New Wichita Falls Office Opening November 7!
We’re excited to announce that our new, larger Wichita Falls office will officially open on November 7, 2024! This new office will replace our current Wichita Falls office and at 7,500 square
read more
Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Dr. Abbey Taught a Course at the American Academy of Ophthalmology 2024 Annual Meeting
For the fifth year, Texas Retina’s Ashkan M. Abbey, MD, taught a continuing medical education (CME) course titled, “Secondary IOL Techniques for Retinal Specialists,” at the annual meeting of the American Academy
read more
Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more